Registry and biorepository for lupus patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter registry and biorepository aims to enroll over 3500 individuals with Systemic Lupus Erythematosus (SLE) over five years. Participants will be categorized into four cohorts based on their condition, including new onset SLE and active lupus nephritis. The study will collect extensive clinical data, patient-reported outcomes, and biological samples for future research on SLE. This initiative seeks to enhance understanding of lupus through comprehensive data collection and biospecimen analysis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Able to understand and comply with study procedures and voluntarily sign a written informed consent document
* Age 18 years or older at the time of enrollment
* Fulfill criteria for SLE based on one or more of the following classifications systems:

Systemic Lupus Erythematosus International Collaborating Clinic (SLICC) 2012 criteria; European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) 2019 criteria; 1997 revised ACR criteria; or Lupus is present per clinical assessment.

Exclusion Criteria:

* Not able to obtain consent
* Not able to meet protocol visit requirements
* Pregnant at the time of enrollment

Where it's running

• University of Alabama at Birmingham
  Birmingham, Alabama, United States Recruiting
• University of Arizona
  Tucson, Arizona, United States Recruiting
• Wallace Rheumatic Studies Center
  Beverly Hills, California, United States Recruiting
• University of Miami
  Miami, Florida, United States Recruiting
• Emory University
  Atlanta, Georgia, United States Recruiting
• University of Chicago
  Chicago, Illinois, United States Recruiting

Study contacts

• Principal investigator: Sam Lim, MD, MPH — Emory University
• Study coordinator: Lupus Nexus Director
• Email: lupusnexus@lupusresearch.org
• Phone: 646-884-6084

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Triple therapy with voclosporin, MMF and prednisolone in lupus nephritis

  This trial tests whether adding voclosporin to standard lupus nephritis treatment (MMF and prednisolone) early on improves kidney inflammation compared to standard therapy alone.

  Recruiting Phase 4 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam · NCT07760480

• Evaluating FT819 for autoimmune diseases

  This study is testing a new treatment called FT819 to see if it can safely help people with moderate to severe autoimmune diseases feel better.

  Recruiting at 21 sites Phase 1 Fate Therapeutics · Beverly Hills, California and 20 other locations · NCT06308978

• Comparing treatments for lupus nephritis without added oral steroids

  This study is testing whether a treatment for lupus nephritis using obinutuzumab and mycophenolate mofetil without steroids can work just as well as a treatment that includes steroids.

  Recruiting Phase 3 Assistance Publique - Hôpitaux de Paris · Paris · NCT04702256

• Long-Term Extension of enpatoran for cutaneous lupus symptoms

  This extension study tests whether continuing enpatoran is safe and helpful for people with skin lupus who completed previous trials, for up to about two years.

  Recruiting Phase 3 EMD Serono · Troy, Michigan · NCT07840287

• Targeting B cells and plasma cells in lupus with a dual-action antibody

  A new injectable therapy (F182112) will be tested in adults with systemic lupus erythematosus to see if it can help by hitting both CD3 on immune cells and BCMA on B cells and plasma cells.

  Recruiting Phase 1 Shandong New Time Pharmaceutical Co., LTD · Shanghai · NCT07829614

• FT839 therapy for autoimmune diseases

  This trial tests FT839, given alone or with rituximab, to see if it is safe and can help people with certain autoimmune diseases who have not responded to other treatments.

  Recruiting Phase 1/2 Fate Therapeutics · Fullerton, California · NCT07800871

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.